Selegiline in Narcolepsy
Authors:
Open Access
- 1 September 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 10 (5) , 491-495
Abstract
We examined the effect of the specific monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl, Eldepryl), 20-30 mg p.o. daily, in 21 subjects with the narcoleptic syndrome for 4 weeks. Selegiline was compared to no treatment (7 subjects) or conventional central stimulant drugs, including dexamphetamine or mazindol (14 subjects). Severity and frequency of narcolepsy, accessory symptoms, and effects of selegiline on mood were measured. Selegiline, as well as causing MAO-B inhibition, is interconverted to amphetamine. Urinary amphetamine and methamphetamine excretion were determined in 18 subjects after 4 weeks on selegiline and the results were compared with amphetamine excretion in subjects on dexamphetamine. The effect of seiegiline, 20–30 mg p.o., on alertness and mood was similar to that of dexamphetamine in the same dosage, with comparable sympathomimetic side effects. Selegiline, 20 mg p.O., caused a subjective increase in alertness for 4–8 h. Mean urinary amphetamine excretion on dexamphetamine, 15–70 mg daily (mean 29 mg) at pH 5.6–6.6, was 5,184 μg/24 h, and on selegiline, 20–30 mg daily (mean 22.5), was 4,127 μg/24 h. We conclude that selegiline, 20–30 mg daily, requires further evaluation in narcolepsy.Keywords
This publication has 5 references indexed in Scilit:
- Amphetamine, mazindol, and fencamfamin in narcolepsy.BMJ, 1985
- Fluvoxamine and clomipramine in the treatment of cataplexy.Journal of Neurology, Neurosurgery & Psychiatry, 1980
- DEPRENYL IN NARCOLEPSYThe Lancet, 1979
- Absence of ?cheese effect? during deprenyl therapy: Some recent studiesJournal of Neural Transmission, 1978
- Treatment of Intractable Narcolepsy with a Monoamine Oxidase InhibitorNew England Journal of Medicine, 1971